Ionis Pharmaceuticals Inc [NASDAQ: IONS] price surged by 2.64 percent to reach at $0.87.
The one-year IONS stock forecast points to a potential upside of 39.63. The average equity rating for IONS stock is currently 1.78, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Ionis Pharmaceuticals Inc [IONS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IONS shares is $55.74 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IONS stock is a recommendation set at 1.78. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Ionis Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 07, 2025. While these analysts kept the previous recommendation, Redburn Atlantic raised their target price to Neutral. The new note on the price target was released on March 31, 2025, representing the official price target for Ionis Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $67 to $60, while BMO Capital Markets kept a Market Perform rating on IONS stock. On July 24, 2024, analysts increased their price target for IONS shares from 53 to 62.
The Average True Range (ATR) for Ionis Pharmaceuticals Inc is set at 1.42, with the Price to Sales ratio for IONS stock in the period of the last 12 months amounting to 7.46. The Price to Book ratio for the last quarter was 11.25, with the Price to Cash per share for the same quarter was set at 13.50.
IONS Stock Performance Analysis:
Ionis Pharmaceuticals Inc [IONS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.13. With this latest performance, IONS shares gained by 17.97% in over the last four-week period, additionally sinking by -14.30% over the last 6 months – not to mention a drop of -21.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IONS stock in for the last two-week period is set at 69.39, with the RSI for the last a single of trading hit 81.55, and the three-weeks RSI is set at 62.04 for Ionis Pharmaceuticals Inc [IONS]. The present Moving Average for the last 50 days of trading for this stock 30.87, while it was recorded at 31.73 for the last single week of trading, and 37.32 for the last 200 days.
Insight into Ionis Pharmaceuticals Inc Fundamentals:
Ionis Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.62 and a Current Ratio set at 9.66.
IONS Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IONS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ionis Pharmaceuticals Inc go to 21.35%.
Ionis Pharmaceuticals Inc [IONS] Institutonal Ownership Details
The top three institutional holders of IONS stocks are: FMR LLC with ownership of 21.89 million shares, which is approximately 15.0008%. VANGUARD GROUP INC, holding 13.85 million shares of the stock with an approximate value of $$659.89 million in IONS stocks shares; and VANGUARD GROUP INC, currently with $$602.41 million in IONS stock with ownership which is approximately 8.6598%.
